Femasys Inc. (NASDAQ:FEMY) Stock Short Interest Declines 71.6%

Femasys Inc. (NASDAQ:FEMY) was the recipient of a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 164,106 shares, a decline of 71.6% from the September 30th total of 577,249 shares. Approximately 2.1% of the company’s shares are short sold. Based on an average daily trading volume, of 108,262 shares, the days-to-cover ratio is presently 1.5 days.

Insider Buying and Selling

In other news, CFO Dov Elefant acquired 15,625 shares of Femasys stock in a transaction dated Friday, August 7th. The shares were bought at an average cost of $3.20 per share, with a total value of $50,000.00. Following the purchase, the chief financial officer owned 15,625 shares in the company, valued at $50,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Kathy Lee-Sepsick bought 15,625 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the chief executive officer owned 15,625 shares of the company’s stock, valued at $50,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 38,750 shares of company stock worth $124,000. 7.75% of the stock is owned by insiders.

Femasys Trading Up 1.8%

Shares of NASDAQ:FEMY traded up $0.03 during midday trading on Friday, hitting $1.38. 51,365 shares of the stock traded hands, compared to its average volume of 259,048. The company has a quick ratio of 0.55, a current ratio of 2.14 and a debt-to-equity ratio of 0.89. The business’s 50 day moving average is $2.31 and its two-hundred day moving average is $6.24. The stock has a market capitalization of $11.56 million, a PE ratio of -0.39 and a beta of -2.16. Femasys has a one year low of $1.30 and a one year high of $22.20.

Femasys (NASDAQ:FEMY) last posted its earnings results on Friday, August 14th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.02). The business had revenue of $0.33 million during the quarter, compared to the consensus estimate of $0.73 million. Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%.

Analyst Ratings Changes

A number of analysts have commented on FEMY shares. Lake Street Capital decreased their price objective on Femasys to $10.00 and set a “buy” rating for the company in a report on Tuesday, August 18th. Wall Street Zen upgraded shares of Femasys from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 17th. Maxim Group reduced their price objective on Femasys to $10.00 and set a “buy” rating for the company in a report on Friday, August 14th. Finally, Weiss Ratings cut Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $50.00.

About Femasys

Femasys Inc is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures.

Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.